Document:

exv10w11

EXHIBIT 10.11

SEPARATION AGREEMENT AND GENERAL RELEASE

     This Separation Agreement and General Release (“Agreement”) is entered into this 30th day of
July, 2008, by and between DAVID S. DOLL (“Doll”), an individual residing at 350 Courtland Avenue,
Harleysville, Pennsylvania 19438 and IMPAX LABORATORIES, INC., a Delaware corporation with offices
located at 121 New Britain Boulevard, Chalfont, Pennsylvania 18914 (the “Company”), who shall be
referred to collectively herein as the “Parties.”

     WHEREAS, the Parties have decided to terminate Doll’s employment with the Company and settle
all outstanding matters between them;

     NOW, THEREFORE, for the mutual consideration set forth herein and intending to be legally
bound, the Parties hereto agree as follows:

     1. Resignation and Termination of Employment Agreement. Doll here by resigns, and the Company
hereby accepts, Doll’s resignation from his employment with the Company, effective as of the close
of business August 1, 2008 (the “Termination Time”). At the Termination Time,

(a) that certain Employment Agreement made as of September 1, 2006 by and between Doll
and the Company (the “Employment Agreement”), including Doll’s rights to the 60,000
Restricted Shares and 60,000 Stock Options granted and to be granted thereunder, and

(b) the fully vested options to purchase 172,500 shares of the Company’s common stock
currently held by Doll,

and all rights and obligations under the Employment Agreement, the Restricted Shares and Stock
Options granted and to be granted thereunder, and the fully vested options shall terminate and

 

 

have
no further force or effect.

     2. Special Separation Benefits.

     In full and complete settlement of all claims Doll may have had under the Employment
Agreement, as well as any and all other claims he has or may have against the Company, its
affiliates, representatives, officers, directors and employees and all other persons who are
defined in the form of Release attached hereto as Exhibit A as “Persons Released,” whether such
claims stem from his employment, the Employment Agreement and/or the cessation of his employment
with the Company or otherwise, through the date of this Agreement, and provided Doll shall have
executed said Release and shall not have exercised his right of revocation under Section 6 hereof,
the Company shall, on August 7, 2008, pay the following separation benefits to Doll:

(a) six hundred twenty thousand dollars ($620,000) in cash (the “Severance Payment”); and

(b) 94,705 shares of the Company’s common stock (the “Shares”);

provided, however, that the Company shall withhold from the payment of the Severance
Payment and Shares such taxes and other deductions as are required by law. The Company believes,
based upon the report of its independent consultant, that the current fair market value of its
common stock is $8.53 per share and that the current fair market value of the Shares is therefore
$807,834. The Company shall withhold, with respect to the taxes relating to the Shares, that
number of Shares having a value of $201,958 (25% of the fair market value of the Shares), based
upon the fair market value per share of $8.53.

     Doll represents that the Shares, which will be issued to David S. Doll and Kathrine M. Doll,
are being acquired by them for their own account, for investment, and not with a view to the
distribution thereof. Doll acknowledges that the Shares have not been registered under the

2

 

Securities Act of 1933, as amended, that they are restricted shares, and that the certificates
representing the Shares shall bear the following restrictive legend:

The shares represented by this certificate have not been registered under the Securities Act
of 1933, as amended, and may not be sold, mortgaged, pledged, hypothecated or otherwise transferred
in the absence of an effective registration statement under the Act or an opinion of counsel
satisfactory to the Corporation that registration is not required under the Act.

At such time as such forms are normally processed for payments made in 2008, the Company shall
issue an IRS Form W-2 to Doll for the Separation Pay and for the value of the Shares.

     3. No Other Compensation. Except as provided in this Agreement, Doll will not be entitled to
any future benefit payment, commission, bonus, allowance, severance or contingent compensation from
the Company by virtue of his employment or the termination thereof and no further payment, benefit
or services will be made or provided to Doll by the Company in consideration for his entering into
this Agreement or otherwise.

     4. Re-employment. Doll shall not seek re-employment with the Company or any affiliate, or any
of their respective successors or assigns, at any time in the future unless the Company shall have
waived such obligation in writing. Should Doll nevertheless seek such re-employment, he hereby
acknowledges that he will not file any action, suit, claim, charge, complaint, grievance or demand
relating to the Company’s or such affiliate’s refusal to hire him.

     5. Releases. In consideration of the Company’s undertakings and agreements hereunder, and
specifically in consideration for the payments and benefits described in Section 2, Doll shall
deliver to the Company an executed Release in the form attached hereto as Exhibit A. The Company
shall deliver to Doll an executed Release in the form attached hereto as Exhibit B. Without
limiting the generality of the forgoing or anything in the Releases, Doll releases the

3

 

Company and
each of the other Persons Released from any and all claims arising from or related to his
employment (and Employment Agreement) with the Company, which he could make on his own behalf, as
well as those which may be made by any other person or organization on his behalf. Doll
specifically waives any right to become, and promises not to become, a member of any class in a
case in which a claim or claims against the Company or any other Persons Released are made
involving any events that took place up to and including the date of this Agreement, except to the
extent that such waiver is prohibited by statute.

     6. Employee Rights. Doll expressly acknowledges that he is aware of his legal right to
consider this Agreement for a period of twenty-one (21) days and that the Agreement will remain
open during this period. At Doll’s sole option, this Agreement may be executed prior to the
expiration of this twenty-one (21) day period. The Company hereby advises Doll to consult with an
attorney prior to executing this Agreement. Doll acknowledges that he has done so, since being
given this Agreement. Further, Doll has the right to revoke this Agreement within seven (7) days
of the execution thereof. Doll expressly agrees that any notice of revocation hereunder shall be
in writing and shall be deemed to have been duly given if received by the Company at the following
address no later than 5:00 p.m. on the seventh (7th) calendar day following the execution of this
Agreement: Impax Laboratories Inc., 121 New Britain Boulevard, Chalfont, PA 18914, Attention:
Arthur A. Koch, Jr., Chief Financial Officer. The Agreement shall not become effective until after
such seven (7)-day period has expired without the Company having received notice of revocation.
Doll understands that if he revokes this Agreement, he will not be entitled to the benefits
provided for hereunder.

     7. No Charges. Doll waives his right to file any charge or complaint, nor will he accept any
relief or recovery from any charge or complaint, before any federal, state, or local

4

 

administrative
agency against the Company or any of the other Persons Released, except as such
waiver is prohibited by statute, for any actions that could or did arise or accrue prior to
and including the date of this Agreement arising from or relating to his employment, the Employment
Agreement, or his separation from the Company; provided, however, that Doll shall not be
prohibited from participating in any investigation or proceeding conducted by the U.S. Equal
Employment Opportunity Commission. Doll further waives all rights to file any other action before
any federal, state, or local court against the Company or any of the other Persons Released for any
actions related to his employment, the Employment Agreement, or his separation from the Company
that could or did arise or accrue prior to and including the date of this Agreement, and he
acknowledges and confirms that no such charge, complaint or action exists in any forum or form
against any of the Persons Released.

     8. No Admissions. By entering into this Agreement, none of the Parties admits to any
wrongdoing against any other Party. Doll acknowledges and agrees that neither this Agreement, nor
the furnishing of the consideration for the Release executed by him, shall be deemed or construed
at any time for any purpose as an admission by the Persons Released of any liability or unlawful
conduct of any kind.

     9. Restrictive Covenants.

          (a) Non-Solicitation. For a period of thirty-six (36) months following the
Termination Time, Doll will not, directly or indirectly, for his own account or for the benefit of
any natural person, corporation, limited liability company, partnership, trust, estate, joint
venture, sole proprietorship, association, cooperative or other entity (collectively, “Persons”),
hire, assist in hiring, solicit, or assist in soliciting, or contact for the purpose of any of the
foregoing, any employee of the Company, or in any way induce, encourage, or cause any employee of
Company

5

 

to leave the employ of Company, or interfere with such employee’s relationship with
Company.

          (b) Non-Disclosure. Doll will not, at any time, directly or indirectly, disclose,
communicate or divulge to any Person, or use for the benefit of himself or any other Person, any
secret, confidential or proprietary knowledge or information with respect to the conduct or details
of the Business of the Company, including customer lists, accounts and information, prospective
customer lists, contractor, subcontractor and vendor lists and information, product research and
development, drug formulations, information relating to planned or contemplated ANDAs, NDAs,
Paragraph 4 filings, methods of operation, pricing, costs, sales, sales strategies and methods,
marketing, marketing strategies and methods, know-how, policies, financial information, financial
condition, business strategies and plans and other information of the Company or its affiliates
which is not generally available to the public and which has been developed or acquired by the
Company or its affiliates with significant effort and expense (“Confidential
Information”). Contemporaneously with the execution of this Agreement, Doll shall deliver to
the Company all Confidential Information (whether in written or electronic form), and all copies of
same, that were made by Doll or otherwise came into his possession or under his control at any time
during his employment by the Company.

          (c) Intellectual Property. Doll represents that he has communicated to the Company
all software, designs, techniques, concepts, methods and ideas, other technical information,
marketing strategies and other ideas and creations pertaining to the Business of the Company that
were conceived or developed by Doll alone, or with others, at any time (during or after business
hours) while Doll was employed by the Company. Doll acknowledges that all such ideas and creations
are inventions and works for hire and are the Company’s exclusive property. Doll will execute any
document that the Company reasonably deems necessary to

6

 

confirm its ownership of such ideas and
creations.

          (d) Non-Disparagement. Neither Doll nor the Company will at any time publish or
communicate any disparaging or derogatory statement or opinion about the other, including, with
respect to the Company, its management, products or services, to any Person; provided,
however, that it shall not be a breach of this provision for either Party to testify truthfully
in any judicial or administrative or other governmental proceeding or to make statements or
allegations in legal filings that are based on such Party’s reasonable belief and are not made in
bad faith.

          (e) Enforcement. Doll acknowledges that the covenants and agreements of this Section
9 herein are of a special and unique character, which give them peculiar value, the loss of which
cannot be reasonably or adequately compensated for in an action at law. Doll further acknowledges
that any breach or threat of breach by him of any of the covenants or agreements will result in
irreparable injury to the Company for which money damages could not be adequate to compensate the
Company. Therefore, in the event of any such breach or threatened breach, the Company shall be
entitled, in addition to all other rights and remedies that the Company may have at law or in
equity, to have an injunction issued by any competent court enjoining and restraining Doll and/or
all other Persons involved therein from committing a breach or continuing such breach. The
remedies granted to the Company in this Agreement are cumulative and are in addition to remedies
otherwise available to the Company at law or in equity. If the Company is obliged to resort to
litigation to enforce any of the covenants that has a fixed
term, then such term shall be extended for a period equal to the period during which a
material breach of such covenant was occurring, beginning on the date of a final court order
(without further right of appeal) holding that such a material breach occurred, or, if later, the
last

7

 

day of the original fixed term of such covenant.

          (f) Acknowledgements. Doll acknowledges that the covenants are a material part of the
consideration bargained for by the Company, and, without Doll’s agreement to be bound by the
covenants, the Company would not have agreed to enter into this Agreement. Doll further
acknowledges and agrees that the Business of the Company and its services are highly competitive
and that the covenants contained in this Section 9 are reasonable and necessary to protect the
Company’s legitimate business interests and Confidential Information. Doll also acknowledges that
the Company has invested significant time, effort, resources and expense in training its employees
and that the restrictions contained in this Section 9 are reasonable and necessary to protect the
Company’s investment and legitimate business interests, and to preserve an undisrupted workplace.

          (g) Scope. If any portion of any covenant or its application is construed to be
invalid, illegal or unenforceable, then the remaining portions and their application shall not be
affected thereby, and shall be enforceable without regard thereto. If any of the covenants is
determined to be unenforceable because of its scope, duration, area or similar factor, then the
court or other trier of fact making such determination shall modify, reduce or limit such scope,
duration, area or other factor, and enforce such covenant to the extent it believes is lawful and
appropriate.

          (h) Indemnification. Each Party shall indemnify, defend and hold harmless the other
in respect of all liabilities, charges, damages, losses, expenses, fees, and costs of any nature
(including reasonable attorney’s fees and costs of litigation) that result from a failure by such
Party to fully perform or comply with any covenant contained in this Section 9.

     10. Disclosure. The Parties understand that the Company may publicly disclose such

8

 

terms of
this Agreement as may be required to comply with its obligations under the Securities Exchange Act
of 1934, as amended, and the rules and regulations thereunder.

     11. Review of Agreement. Doll acknowledges that he has carefully read and fully understands
the provisions of this Agreement, including the release contained herein, and that he has had a
reasonable and sufficient time and opportunity to consult with his attorney.

     12. Construction and Amendment. In entering into this Agreement, Doll acknowledges that he
has not relied on any representation or statement, whether oral or written, other than set forth in
this Agreement. This Agreement contains all of the terms of the Parties’ agreement and shall not
be modified or changed other than by the written agreement of all Parties. The language of this
Agreement shall in all cases be construed as a whole, according to its fair meaning and not
strictly for or against either of the Parties. Should any provision of this Agreement be declared
unlawful or unenforceable by any court of competent jurisdiction and cannot be modified to be
enforceable, such provision shall become null and void, leaving the remainder of this Agreement in
full force and effect.

     13. Choice of Law and Forum. This Agreement shall be interpreted under the laws of the
Commonwealth of Pennsylvania, and any action to enforce its terms shall be brought in a court of
competent jurisdiction in the Commonwealth of Pennsylvania.

     14. Entire Agreement. This Agreement sets forth the entire agreement between the parties
hereto, and fully supersedes any prior agreements or understandings between the parties.

PLEASE READ THIS AGREEMENT CAREFULLY, AS IT CONTAINS A RELEASE OF
ALL KNOWN AND UNKNOWN

9

 

CLAIMS. BY SIGNING THIS AGREEMENT, DAVID S. DOLL ACKNOWLEDGES THAT
HE HAS READ THE AGREEMENT, UNDERSTANDS IT AND IS VOLUNTARILY
ENTERING INTO IT.

	 	 	 	 	 
	Dated: July 30, 2008 	/s/ David S. Doll
 	 
	 	David S. Doll 	 
	 	 	 
	 	Impax Laboratories, Inc.

 	 
	Dated: July 30, 2008 	By:  	/s/ Larry Hsu
 	 
	 	 	Larry Hsu 	 

10

 

	 	 	 	 	 

Exhibit A

RELEASE

I, David S. Doll, do hereby agree as follows:

In consideration of the payments and other benefits to be provided to me by Impax Laboratories,
Inc. (“the Company”) as described in the Separation Agreement dated July 30, 2008, to which the
form of this Release is annexed as Exhibit A (the “Agreement”), and for other good and valuable
consideration as described in the Agreement, receipt of which I hereby acknowledge, I do hereby
forever release and discharge the Company and its present and former parents, subsidiaries,
divisions, affiliated entities, partners, joint venturers, predecessors, successors and assigns,
all of their respective shareholders, officers, directors, agents, attorneys, servants and
employees (hereafter referred to separately and collectively as the “Persons Released”), from any
and all claims, demands, debts, liabilities, accounts, obligations, costs, expenses, liens,
actions, causes of action and remedies of any nature whatsoever, known or unknown, arising from the
beginning of time until the date of this Release (hereinafter referred to collectively as
“Claims”), including with specific emphasis, but without limitation, (1) any and all claims under
the Employment Agreement made as of September 1, 2006 by and between the Company and me (the
“Employment Agreement”) (2) any and all claims for employee benefits under the Employee Retirement
Income Security Act of 1974, as amended; (3) any and all claims of employment discrimination on any
basis under Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in
Employment Act of 1967, as amended (the “ADEA”), the Civil Rights Act of 1866, the Immigration
Reform and Control Act of 1986, the Pennsylvania Human Relations Act; (4) any and all claims under
other federal, state, local or foreign laws, whether based on contract, tort, or other legal or
equitable theory of recovery; and (5) any and all claims for attorneys’ fees; provided,
however, that this Release shall not impair my right or ability to enforce the Company’s
obligations as set forth in the Agreement. This Release is given by me for me, and my agents,
representatives, heirs, family, successors and assigns, and shall be binding on all of them.

I acknowledge that as of the date of this Release there are no further payments or benefits
promised or otherwise due in the future to me by or from the Company, except only any payments
specifically described in and to be made under the Agreement.

I agree that I will not hereafter assert any Claims against the Persons Released for any acts or
omissions occurring from the beginning of time through the date of this Release. By entering into
this Release, I do not waive rights or claims that arise after the date this Release is executed.

For a period of seven (7) days following the execution of this Release, I have the right to revoke
this Release. This Release shall not become effective or enforceable until the revocation period
of seven (7) days has expired. Any such revocation must be made in a signed letter executed by me
and received by the Company at the following address no later than 5:00 p.m. on the seventh

 

 

day after execution of this Release: Impax Laboratories, Inc., 131 New Britain Boulevard, Chalfont,
Pennsylvania 18914, Attention: Arthur A. Koch, Jr., Chief Financial Officer.

I acknowledge that I have been advised and urged by the Company in writing to consult with an
attorney prior to executing this Release. I further represent and warrant that the Company has
given me a period of at least twenty-one (21) days in which to consider this Release before
executing the same.

Acceptance by me of the monies or benefits paid or provided by the Company, as described in the
Agreement, at any time more than seven (7) days after the execution of this Release shall
constitute an admission by me that I did not revoke this Release during the revocation period of
seven (7) days and shall further constitute an admission that this Release has become effective and
enforceable.

If I execute this Release at any time prior to the end of the twenty-one (21) day period that the
Company gave to me in which to consider this Release, such early execution was a knowing and
voluntary waiver of my right to consider this Release for at least twenty-one (21) days, and was
due to my belief that I had ample time in which to consider and understand this Release and in
which to review the same with an attorney.

I ACKNOWLEDGE, REPRESENT, AND WARRANT THAT I HAVE CAREFULLY READ THIS RELEASE; THAT I FULLY
UNDERSTAND ITS TERMS, CONDITIONS AND SIGNIFICANCE; THAT I HAVE HAD AMPLE TIME TO CONSIDER AND
NEGOTIATE THIS RELEASE; THAT THE COMPANY HAS ADVISED AND URGED ME TO CONSULT WITH AN ATTORNEY
CONCERNING THIS RELEASE; THAT I HAVE HAD A FULL OPPORTUNITY TO DO SO, AND THAT I HAVE EXECUTED THIS
RELEASE VOLUNTARILY AND KNOWINGLY, AND WITH SUCH ADVICE AS I DEEMED APPROPRIATE.

I acknowledge and agree that this Release constitutes a “general release” and extends to all
claims, whether or not known to or suspected by me prior to the execution of this Release. I,
absolutely and forever, release and waive all of my rights under any federal or state statute
limiting the scope of a general release. I agree that if this Release does not become effective for
any reason, this Release shall be deemed negotiation for settlement only and will not be admissible
in evidence or usable for any purpose whatsoever in connection with or at any trial or appeal in
connection with any action.

 

 

This Release shall be governed by and construed under the laws of the Commonwealth of Pennsylvania
applicable to contracts to be performed wholly within such state. I declare that there are no
other discussions, negotiations, commitments or understandings that are not set forth herein or in
the Agreement.

     IN WITNESS WHEREOF, I have executed this Release to have immediate effect from and after this
30th day of July 2008.

	 	 	 	 	 
	 	/s/ David S. Doll
 	 
	 	David S. Doll 	 
	 	 	 
	 	
 	 
	 	Social Security Number 	 

 

 

	 	 	 	 	 

Exhibit B

Impax Laboratories, Inc. hereby agrees as follows:

     In consideration of the promises and mutual agreements contained in the Separation Agreement
dated July 30, 2008 to which the form of this Release is attached as Exhibit B (the “Agreement”),
Impax Laboratories, Inc. (“the Company”) agrees that, except as otherwise provided, it will not at
any time assert a claim or institute any action in respect of, and hereby knowingly and voluntarily
remises, releases and forever discharges David S. Doll ( the “Releasing Party”) from any and all
actions or causes of action, suits, injuries, debts, claims, charges, losses, damages, expenses,
complaints, grievances, contracts (whether oral or written, express or implied from any source) and
promises whatsoever, in law or equity, which the Company ever had or may have against the Releasing
Party, including those unknown, undisclosed and unanticipated, for, upon, or by reason of any
matter, cause or thing whatsoever which occurred up to the date of the Agreement, (other than
claims arising out of criminal acts or willful misconduct), including any and all claims arising
out of, relating to, or based upon, his employment by the Company, or any alleged violation of
local, state or federal law, regulation or ordinance, and/or public policy, contract, tort or
common law, and including any claims for costs, attorneys’ fees, or other expenses. There is
excepted from this Release any claims relating to the obligations of the Releasing Party to the
Persons Released pursuant to the Agreement or relating to the enforcement of the rights of the
Persons Released thereunder.

	 	 	 	 	 
	 	Impax Laboratories, Inc.

 	 
	 	By 	/s/ Larry Hsu
 	 
	 	 	Larry Hsuexv10w12

EXHIBIT 10.12

CONSULTING AGREEMENT

     This Consulting Agreement (“Agreement”) is made effective as of September 4, 2008 (the
“Effective Date”) by and between Impax Laboratories, Inc. (“Impax”), a Delaware corporation, having
a principal place of business at 30831 Huntwood Avenue, Hayward, California 94544, and David S.
Doll, a resident of the State of Pennsylvania, (hereinafter “Consultant”), having an address at 350
Courtland Ave, Harleysville, PA 19438.

     Whereas, Impax presently is engaged in the business of developing, manufacturing and selling
pharmaceutical dosage forms; and

     Whereas, Consultant, by virtue of his background, training and ability, is prepared to enter
into this Agreement with Impax as a Consultant;

     NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set
forth, and intending to be legally bound, the parties hereto agree as follows:

	1.	 	Relationship of the Parties

	 	1.1	 	Impax and Consultant intend that the relationship established between them shall be that
of client and independent contractor. Consultant is not to be considered an agent or employee of
Impax for any purpose, nor is any agent, or employee of Consultant to be considered an employee or
agent of Impax.
	 
	 	1.2	 	None of the benefits provided by Impax to its employees, including, but not limited to,
worker’s compensation insurance, health insurance and unemployment insurance, is available from
Impax to Consultant, or to the employees or agents of Consultant. As an independent contractor,
Consultant shall be solely responsible for payment of any and all applicable taxes. Impax shall
not be responsible for paying any social security, withholding tax, unemployment insurance, medical
insurance, liability insurance, worker’s compensation insurance or any other type of similar
expense on behalf of Consultant or his employees.

	2.	 	Services to be Performed

-1-

 

	 	2.1	 	Consultant shall provide the services described in Exhibit A attached hereto
(the “Services”) and shall provide the Services contemplated therein at a time and
place convenient to both parties, and shall supply any equipment necessary to perform
the Services. Impax waives any right to direct, instruct and control Consultant as to
the manner in which Consultant achieves the general and specific objective of the
delivery of the Services. Consultant agrees to perform the work in a manner which is
consistent with good business practices.
	 
	 	2.2	 	No Conflicting Obligations. Consultant represents and warrants that the
performance of the Services under this Agreement will not conflict with any other
obligation of the Consultant to any third party or result in breach of any agreement
with any third party. Consultant further agrees that Consultant will not bring or use
any documents, materials or information of any third party that are not generally
available to the public in the performance of the Services hereunder. Should a
potential conflict arise or should Consultant become aware of a potential conflict
during the course of Consultant’s work under this Agreement, Consultant shall
immediately present the potential conflict to Impax for Impax’s review.
	 
	 	2.3	 	Consultant may not assign this Agreement or any of the duties hereunder without
Impax’s written consent.

	3.	 	Compensation

Consultant shall be compensated for Services performed under this Agreement in the manner
set forth in Exhibit A.

	4.	 	Confidentiality

	 	4.1	 	Nondisclosure. At all times during and after the term of Consultant’s
relationship with Impax, Consultant shall not, except with Impax’s prior written
consent, or except in the proper course of performance of the Services, directly or
indirectly, disclose, communicate or divulge to any third party, or use for its own
benefit or the benefit of any other party, any information that is not publicly known,
including confidential or proprietary knowledge or information concerning the conduct
or details of Impax’s business, including without limitation, names of drugs being
pursued by Impax, details of contracts, technical know-how, methods of operation,
marketing methods, trade secrets, pricing or other policies, prospects and

-2-

 

	 	 	 	financial condition (“Impax Information”). These provisions shall not apply to any
information that is:

a) independently developed by or for the Consultant without having contact with and
not being aware of the content of Impax Information supplied hereunder, as evidenced
by the Consultant’s written records; b) is disclosed to the Consultant without
restriction after acceptance of this Agreement by a third party having a legal right
to make such disclosure; or c) is or becomes part of the public domain through no
breach of this Agreement by the Consultant.

	 	4.2	 	Effect of Termination. Upon termination or expiration of this
Agreement, Consultant shall immediately return to the Impax all copies of Impax
Information, provided, however, that Consultant may retain one copy of any materials
needed for legal, regulatory or audit purposes. Such retained materials shall be
subject to the confidentiality and non-use provisions set forth above.
	 
	 	4.3	 	Remedies. Consultant acknowledges that any breach of this Section 4
will result in irreparable injury to Impax for which money damages would not adequately
compensate. In the event of any such breach, Impax shall be entitled, in addition to
all other rights and remedies which Impax may have at law or in equity, to have an
injunction issued by any competent court enjoining and restraining Consultant and all
other persons involved therein from such breach.
	 
	 	4.4	 	Publication. Consultant will not publish any data or information
developed under this Agreement without the express written consent of Impax.

	5.	 	Intellectual Property

	 	5.1	 	Disclosure. Consultant will promptly disclose to Impax all inventions,
developments, improvements, designs, formulas and/or processes made, conceived or first
reduced to practice, either alone or jointly with others, in the performance of the
Services (“Inventions”).
	 
	 	5.2	 	Assignment. Consultant agrees that any copyrightable works prepared in
the performance of the Services are “works for hire” under the Copyright Act and that
Impax will be considered the author and owner of such copyrightable works. Consultant
further agrees that all Inventions will be

-3-

 

	 	 	 	the sole and exclusive property of Impax and hereby assigns its right in any such
Inventions to Impax. Consultant agrees to assist Impax, at Impax’s expense, in
obtaining and enforcing any intellectual property rights pursuant to this Agreement,
and to execute any documents as reasonably requested by Impax for such purposes.

	6.	 	Term and Termination

	 	6.1	 	The term of this Agreement shall begin on the effective date stated hereinabove
and shall continue for a period of one year, unless extended by written agreement of
the parties or sooner terminated as provided herein.
	 
	 	6.2	 	Impax may terminate this Agreement for any reason or no reason upon forty-five
(45) days written notice to the other party. Consultant may terminate this Agreement
in the event of a material breach by Impax, which breach has not been cured within
forty-five (45) days notice of such breach.
	 
	 	6.3	 	Sections 3, 4, 5 and 6 shall survive termination or expiration of this
Agreement.

	7.	 	Miscellaneous

	 	7.1	 	This Agreement constitutes the entire agreement of the parties and supersedes
all prior or contemporaneous agreements and understandings related to the subject
matter hereof, written or oral. No amendment to any provision of this Agreement shall
be binding on the parties unless in writing. The rights, obligations, duties and
agreements of the parties hereto shall issue to and be binding on their respective
heirs, administrators, executors, personal representatives, successors and assigns,
except as otherwise herein provided.
	 
	 	7.2	 	No waiver of any provision of this Agreement shall be interpreted to operate as
a waiver with respect to any future obligation or as to any other provision of this
Agreement.
	 
	 	7.3	 	If any terms, condition, clause or provision of this Agreement is determined to
be invalid or unenforceable, then such clause shall be construed to be replaced with a
valid provision most closely resembling the parties’ intent, and all other terms shall
continue in full force and effect.

-4-

 

	 	7.4	 	This Agreement shall be governed by and interpreted under the laws of the State
of California without giving effect to the choice of law principles thereof.
	 
	 	7.5	 	Notices under this Agreement shall be given in writing to the parties at the
addresses set forth above or to such other address as the parties may subsequently
designate. Notices shall be deemed given when deposited in the United States mail
postage pre-paid by certified or registered mail, or when delivered to a recognized
express mail delivery carrier in accordance with this paragraph.

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date set
forth above.

	 	 	 
	Impax Laboratories, Inc.

	 	David S. Doll
	 
	 	 
	By: /s/ Larry Hsu

	 	By: /s/ David Doll
	 
	 	 
	Name: Larry Hsu

	 	Name: David Doll
	 
	 	 
	Title: President and CEO

	 	Title:
	 
	 	 
	Date: September 4, 2008

	 	Date: September 4, 2008

-5-

 

Consultant’s Services

Consultant will provide litigation assistance as requested by the Company including the following:

	 	•	 	Keep available the two weeks starting on November 3, 2008, in order to travel to
Delaware and serve as a trial witness in the Tricor trial;
	 
	 	•	 	Review documents and provide information and assistance to the Company’s litigation
counsel;
	 
	 	•	 	Work with the Company’s litigation counsel to prepare for trial testimony in the Tricor
litigation; and
	 
	 	•	 	Work with the Company’s litigation counsel to prepare for and serve as a deposition
witness in the Axcan litigation, if necessary.

If Consultant is requested by the Company to perform additional services, and Consultant is willing
to do so, the parties will agree on appropriate terms for such services prior to the performance of
such services, such terms to be agreed in writing and incorporated as an amendment to this
Agreement.

Compensation

Consultant will be granted 9,836 shares of Impax common stock within thirty (30) days of execution
of this Agreement. Consultant represents that the shares are being acquired for his own account,
for investment, and not with a view to the distribution thereof. Consultant acknowledges that the
shares will not have been registered under the Securities Act of 1933, as amended, that they are
restricted shares, and that the certificates representing the shares shall bear the following
restrictive legend:

The shares represented by this certificate have not been registered under the
Securities Act of 1933, as amended, and may not be sold, mortgaged, pledged,
hypothecated or otherwise transferred in the absence of an effective
registration statement under the Act or an opinion of counsel satisfactory to
the Corporation that registration is not required under the Act.

Consultant will be compensated at the rate of two hundred and seventy-five dollars ($275) per hour
for time spent providing the Services. Consultant will not be compensated for time spent in
travel.

In addition, Consultant will be reimbursed for reasonable travel-related expenses incurred in the
performance of the Services, if such travel is requested by Impax. Examples of reasonable travel
related expense include round trip coach air fare, local transportation, parking, meals,

-6-

 

and lodging. Consultant is required to use Impax designated travel service to book air travel at
least twenty-one (21) days (if possible) in advance. Receipts for reimbursable expenses should be
sent to Meg Snowden at Impax. Reimbursement by Impax shall be within forty-five (45) days from
receipt of expense report documentation.

-7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]